XML 39 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Unaudited Condensed Consolidated Statements of Loss and Comprehensive Loss - GBP (£)
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Unaudited Condensed Consolidated Statements of Loss and Comprehensive Loss [Abstract]        
Product revenue, net £ 45,514,000 £ 23,992,000 £ 87,566,000 £ 31,674,000
Pre-product revenue, net 0 3,708,000 0 6,537,000
Total revenue from sale of therapies 45,514,000 27,700,000 87,566,000 38,211,000
Collaboration revenue 2,250,000 4,302,000 4,739,000 16,265,000
Total revenue 47,764,000 32,002,000 92,305,000 54,476,000
Cost of product revenue (886,000) (34,000) (1,064,000) (282,000)
Research and development expenses (28,767,000) (20,150,000) (57,216,000) (38,731,000)
Selling and administrative expenses (33,884,000) (18,811,000) (67,185,000) (38,916,000)
Operating loss (15,773,000) (6,993,000) (33,160,000) (23,453,000)
Finance income 3,412,000 118,000 5,958,000 128,000
Finance costs (1,565,000) (1,397,000) (3,185,000) (2,730,000)
Net finance income / (costs) 1,847,000 (1,279,000) 2,773,000 (2,602,000)
Loss before taxation (13,926,000) (8,272,000) (30,387,000) (26,055,000)
Income tax (charge) / credit (151,000) 2,151,000 (387,000) 3,806,000
Loss for the period (14,077,000) (6,121,000) (30,774,000) (22,249,000)
Other comprehensive income / (loss) that is or may be reclassified to profit or loss in subsequent periods:        
Exchange differences on translation of foreign operations 1,054,000 (323,000) 1,434,000 (118,000)
Total other comprehensive income / (loss) for the period 1,054,000 (323,000) 1,434,000 (118,000)
Total comprehensive income / (loss) for the period £ (13,023,000) £ (6,444,000) £ (29,340,000) £ (22,367,000)
Basic loss per share (in pounds per share) £ (0.29) £ (0.14) £ (0.64) £ (0.51)
Diluted loss per share (in pounds per share) £ (0.29) £ (0.14) £ (0.64) £ (0.51)